Germany ‘won’t approve’ AstraZeneca vaccine for over-65s
Committee says there is not enough data to recommend jab for older age groups
Your support helps us to tell the story
This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.
The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.
Help us keep bring these critical stories to light. Your support makes all the difference.
Germany has recommended the AstraZeneca coronavirus vaccine should only be given to people under the age of 65.
The country’s vaccine committee said a lack of sufficient data on the effectiveness of the inoculation in older people was the reason for the decision in a draft recommendation.
The European Medicines Agency is expected to approve the AstraZeneca vaccine, developed alongside the University of Oxford, for use in the 27-nation European Union on Friday.
It would be the third cleared for use in the EU after the BioNTech-Pfizer and Moderna vaccines.
Germany and AstraZeneca were both forced to deny German media reports that the vaccine was substantially less effective among the over-65s on Wednesday.
The pharmaceutical giant strongly refuted the claims in a written statement, saying “reports that the AstraZeneca/Oxford vaccine efficacy is as low as 8 per cent in adults over 65 years are completely incorrect”.
It also recently became embroiled in a row with the EU after it told the bloc the volume of its vaccine deliveries would be 60 per cent lower than initially promised for the first quarter of this year.
The German health minister, Jens Spahn, stressed that the committee’s recommendation was not its final decision, and that this would only be made once the vaccine is cleared for use.
But he said there had been a discussion since autumn about there being a lack of data in studies on the AstraZeneca vaccine’s effectiveness in older groups.
“It was to be expected that this would have an influence on the decision of the regulatory authorities and then the permanent vaccine commission,” Mr Spahn said.
“We just don’t know yet how concretely – so let’s wait for the decision tomorrow on clearance and then the final recommendation from the permanent vaccine commission.”
Boris Johnson joined Public Health England (PHE) in defending the use of the jab after Germany’s draft recommendation.
Asked if he is concerned about the verdict, the prime minister told reporters: “No, because I think the MHRA, our own authorities have made it very clear that they think the Oxford/AstraZeneca vaccine is very good and efficacious, gives a high degree of protection after just one dose and even more after two doses.
“And the evidence they’ve supplied is they think it’s effective across all age groups and provides a good immune response across all age groups.”
He added: “I don’t agree with that.”
Additional reporting by AP and PA
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments